Cann Pharma secures TGA manufacturing licence, strengthening Crisci Group’s GMP manufacturing capabilities
14 October 2026
The Crisci Group and Cann Health Group are proud to announce that Cann Pharma has received its TGA manufacturing licence, marking an important milestone in the continued growth of the Group’s pharmaceutical manufacturing capabilities.
The licence enables Cann Pharma to operate as a TGA-licensed manufacturing facility, meeting the requirements of Good Manufacturing Practice (GMP) and strengthening the Group’s ability to deliver high-quality pharmaceutical manufacturing services. This follows the expansion of IWG Pharma International
The achievement adds another GMP manufacturing capability to the Crisci Group portfolio and reflects the Group’s continued investment in specialised facilities, quality systems and Australian pharmaceutical manufacturing. Following the establishment of IWG Pharma International earlier this year as a GMP and TGA-registered manufacturing facility.
For Cann Health Group, the milestone represents the culmination of significant work across the Cann Pharma team, from facility development and quality systems through to regulatory requirements and manufacturing processes.
David Crisci, Founder and CEO of Crisci Group and Cann Health Group, said:
“Receiving our TGA manufacturing licence is a significant achievement for Cann Pharma and an important milestone for the wider Crisci Group.
“A great deal of work has gone into establishing the facility, developing robust quality systems and meeting the requirements necessary to operate to GMP standards. We are incredibly proud of the team and the expertise that has brought us to this point.
The addition of Cann Pharma to the Group’s GMP manufacturing portfolio further expands the capabilities available across the Crisci Group, supporting its broader vision of providing specialised pharmaceutical, compounding and health manufacturing services under one organisation.
About Cann Pharma
Cann Pharma is the pharmaceutical manufacturing division of Cann Health Group, part of the Australian-owned Crisci Group. Cann Pharma operates from a purpose-built manufacturing facility and provides pharmaceutical manufacturing services supported by GMP-aligned quality systems and processes.
Enquiries:
John Koekemoer